CardieX Announces Filing of Form F-1 for Public Offering and Dual Listing on Nasdaq
Cardiex Limited
1 1

CardieX Announces Filing of Form F-1 for Public Offering and Dual Listing on Nasdaq

CardieX Limited (ASX: CDX), an Australian cardiovascular monitoring solutions provider, has publicly filed a registration statement on Form F-1 with the U. S. Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of American Depositary Shares (ADSs) representing its ordinary shares. The ADSs will subsequently be listed on the Nasdaq Capital Market under the ticker symbol "CDEX. "

Comprehensive Filing for Dual Listing

The registration statement lodged with the SEC is comprehensive and mirrors that of a prospectus in an Australian IPO. The Offering is subject to shareholder approval for the issue of ordinary shares, which will be sought at an extraordinary general meeting of shareholders. The approval process is expected to commence soon, and the Offering is also subject to general market conditions.

Story Continues.. after this ad because we need some dollarydoos

There is no guarantee as to the size and terms of the Offering, launch or completion, and when they will occur.

Lead book-runner and Offering Details

The Offering will be led by Roth Capital Partners, and no details regarding the number of ADSs to be sold, issue price, or number of ordinary shares represented by each ADS have been determined. The Offering will only be made available via a prospectus. Copies of the preliminary prospectus can be obtained from Roth Capital Partners.

Dual Listing, Not Delisting

CardieX's ordinary shares are currently being traded on the Australian Securities Exchange (ASX) under the symbol "CDX," and this public filing does not represent their delisting from the ASX. If the Offering is successful, CardieX will be dual listed on both the ASX and Nasdaq, marking its presence globally.

Future Developments

The registration statement on Form F-1 has been filed with the SEC but has not yet been effective. Therefore, no securities may be sold until the registration becomes effective.

As more developments become available, interested investors and shareholders can expect to learn more about CardieX's progress and expansion as the company seeks to grow and expand its presence internationally.

Promote your business on our growing investor platform: Advertise With Us

Like

Reply 217 Share